Welcome to our dedicated page for Dolby Laboratories SEC filings (Ticker: DLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dolby Laboratories earns most of its revenue from licensing breakthrough formats like Dolby Atmos and Dolby Vision, so every footnote in a 10-K or 10-Q matters. Royalty rates, unit shipments, and new patent wins are buried deep in the text—making DLB filings uniquely data-dense for a company with minimal physical inventory.
Stock Titan’s AI engine dissects each document the moment it hits EDGAR. Whether you need a Dolby Laboratories quarterly earnings report 10-Q filing to gauge device penetration, or want Dolby Laboratories insider trading Form 4 transactions in real time, our platform translates legalese into clear language and trend charts. The same AI model answers natural questions such as “understanding Dolby Laboratories SEC documents with AI” or “Dolby Laboratories 8-K material events explained,” so you never waste time hunting for a single note about deferred revenue.
- 10-K & 10-Q: Royalty streams, segment margins, R&D spend—see the Dolby Laboratories annual report 10-K simplified with key tables extracted.
- Form 4: Track Dolby Laboratories executive stock transactions Form 4 alongside price charts for context.
- 8-K & press releases: Immediate alerts when new license deals or litigation updates drop.
- Proxy (DEF 14A): Dig into Dolby Laboratories proxy statement executive compensation to see how bonuses tie to royalty growth.
Analysts use these insights to compare quarter-over-quarter royalty trends, monitor patent litigation disclosures, and spot insider sentiment shifts. From “Dolby Laboratories Form 4 insider transactions real-time” to “Dolby Laboratories earnings report filing analysis,” every document is parsed, summarized, and linked—saving hours and sharpening decisions.
Kevin J. Yeaman, President and CEO and director of Dolby Laboratories (DLB), reported option exercise and an immediate sale of shares on 08/12/2025. He exercised an employee stock option to acquire 25,000 shares of Class A common stock at an exercise price of $45.50 per share and simultaneously sold 25,000 shares at a weighted-average sale price of $72.3131 per share. Following these transactions, the reporting person beneficially owns 139,725 shares of Class A common stock indirectly through the Kevin and Rachel Yeaman Family Trust; this total includes 127,735 shares underlying restricted stock units that remain subject to forfeiture until they vest. The filing also notes the exercised option was part of a larger grant covering 194,399 shares, and the sold shares were transacted in multiple sales at prices ranging from $71.63 to $72.59.
Dolby Laboratories (DLB) Form 144 shows a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney on 08/12/2025 with an aggregate market value of $1,807,827.50. The filing lists 95,844,185 shares outstanding, and the securities were acquired the same day by stock option exercise with payment in cash. The notice also records multiple recent sales by Yeaman Family Trust between 06/10/2025 and 07/16/2025 in several tranches. By signing, the seller represents they are not aware of any undisclosed material adverse information; a Rule 10b5-1 plan date is not indicated.
Dolby Laboratories (NYSE:DLB) CEO Kevin Yeaman filed a Form 4 for transactions on 06/24/2025.
- Exercised 25,000 options at $45.50.
- Immediately sold the same 25,000 Class A shares at a weighted-average $74.02, generating ≈$1.85 million in gross proceeds.
- Sale represents about 18 % of the shares held in his family trust.
- Post-trade holdings: 114,725 Class A shares (trust), 127,735 unvested RSUs, and 135,615 unexercised options.
The trades were executed under a Rule 10b5-1 plan; no additional corporate events were disclosed.
Dolby Laboratories (DLB) insider filing reports planned sale of 25,000 shares of common stock with an aggregate market value of $1,850,530. The securities were acquired through a stock option exercise on June 24, 2025, and are planned to be sold through Morgan Stanley Smith Barney LLC on the NYSE.
The filing also discloses recent trading activity by the Yeaman Family Trust, which sold:
- 25,000 shares for gross proceeds of $1,905,650 on June 10, 2025
- 8,683 shares for gross proceeds of $661,829 on June 10, 2025
This Form 144 represents a notice of proposed sale of securities pursuant to Rule 144 under the Securities Act of 1933. The total shares to be sold represent approximately 0.026% of Dolby's outstanding shares (96,066,188 shares).
FAQ
What is the current stock price of Dolby Laboratories (DLB)?
What is the market cap of Dolby Laboratories (DLB)?
